Aspira Women’s Health (NASDAQ:AWH) Coverage Initiated by Analysts at StockNews.com

Equities researchers at StockNews.com assumed coverage on shares of Aspira Women’s Health (NASDAQ:AWH) in a note issued to investors on Thursday. The firm set a “hold” rating on the stock.

Separately, Alliance Global Partners cut their price target on shares of Aspira Women’s Health from $7.00 to $5.50 and set a “buy” rating on the stock in a report on Wednesday, August 14th.

Aspira Women’s Health Price Performance

AWH stock opened at $0.86 on Thursday. Aspira Women’s Health has a 52 week low of $0.74 and a 52 week high of $5.65. The company has a market cap of $13.81 million, a price-to-earnings ratio of -0.59 and a beta of 1.44. The business has a fifty day simple moving average of $0.88 and a 200-day simple moving average of $1.53.

Aspira Women’s Health (NASDAQ:AWH) last announced its quarterly earnings results on Monday, August 12th. The company reported ($0.28) EPS for the quarter, topping the consensus estimate of ($0.32) by $0.04. The firm had revenue of $2.42 million for the quarter, compared to analyst estimates of $2.60 million. During the same quarter in the prior year, the company earned ($0.28) earnings per share. As a group, analysts expect that Aspira Women’s Health will post -1.26 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Aspira Women’s Health

An institutional investor recently raised its position in Aspira Women’s Health stock. B. Riley Wealth Advisors Inc. increased its position in Aspira Women’s Health Inc. (NASDAQ:AWH) by 88.6% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 236,396 shares of the company’s stock after purchasing an additional 111,022 shares during the quarter. B. Riley Wealth Advisors Inc. owned 1.90% of Aspira Women’s Health worth $352,000 as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 12.19% of the company’s stock.

Aspira Women’s Health Company Profile

Aspira Women's Health Inc, together with its subsidiaries, discovers, develops, and commercializes of noninvasive AI-powered diagnostic tests for gynecologic diseases in the United States. The company's products include Ova1Plus, a qualitative serum test to assess the likelihood of malignancy in women with an ovarian adnexal mass; Overa, a biomarker test intended to maintain Ova1's high sensitivity; and OvaWatch, a laboratory developed tests to assist in the initial clinical assessment of malignancy risk in all women thought to have an indeterminate or benign adnexal mass.